

FORM 51 – 102F3
MATERIAL CHANGE REPORT

Item 1: Name and Address of Company

BioMark Diagnostics Inc. (“the Issuer”)
165 – 10551 Shellbridge Way
Richmond, BC V6X 2W8

Item 2: Date of Material Change

June 15, 2017

Item 3: News Release

A news release was issued and disseminate on June 20, 2017 and filed on SEDAR (www.sedar.com).
A copy of the news release is attached as Schedule “A” hereto.

Item 4: Summary of Material Change

The Company announced that effective June 15th, 2017, Ms. GUOYU HUANG, MBA, has been appointed as Interim Chief Financial Officer.

Item 5: Full Description of Material Change

Please see attached Schedule “A”

Item 6: Reliance on subsection 7.1(2) of National Instrument 51-102

Not applicable

Item 7: Omitted Information

None

Item 8: Executive Officer

Rashid Ahmed Bux, President & CEO
Telephone: 604.282.6567
Email: info@biomarkdiagnostics.com

Item 9: Date of Report

June 20, 2017



BIOMARK APPOINTS Ms. GUOYU HUANG AS INTERIM CFO

June 20th, 2017 - Vancouver, British Columbia - BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that effective June 15, 2017, Ms. Guoyu Huang, MBA, has been appointed as Interim Chief Financial Officer.

Ms. Huang has over 6 years experience in the biotechnology sector and successfully managed financial transactions, audit, and project management activities. Over the past 2 years, Ms. Huang was instrumental in the listing of the company on the CSE. In 2016, Ms. Huang completed Good Clinical Practice Certificate program at Saint Boniface Research Center and most recently participated in Financing, Governance, and Compliance course offered by SFU in Vancouver, BC for public companies.

In connection with the appointment of Ms. Huang to Interim CFO, the Company has granted stock options to purchase 250,000 shares, exercisable at a price of \$0.15 per share for a period of five years.

Abbey Abidye will step down as CFO but will provide the necessary transitional support as needed. Management and the Board of Directors would like to thank Mr. Abidye for his hard work and contributions to the Company.

About BioMark Diagnostics Inc.

BioMark Diagnostics is developing proprietary, non-invasive, and accurate cancer diagnostic solutions, which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors. For more information please visit the company website at: www.biomarkdiagnostics.com

On Behalf of the Board of Directors

BIOMARK DIAGNOSTICS INC.

“Rashid Ahmed Bux”

CEO and Director

Contact Information

Rashid Ahmed Bux – President & CEO

BioMark Diagnostics Inc.

Tel. 604-282-6567

Email: info@biomarkdiagnostics.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any applicable securities laws or any state of the United States and may not be offered or sold in the United States or to the account or benefit of a person in the United States absent an exemption from the registration requirements.

The CSE has not reviewed, approved or disapproved the content of this press release.